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TFAP2A Mutations Result
in Branchio-Oculo-Facial Syndrome
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Roberto T. Zori,5 Michelle N. Burch,5 Michele Clemens,6 John B. Mulliken,7 Rosemarie Smith,8
and Angela E. Lin9
Branchio-oculo-facial syndrome (BOFS) is a rare autosomal-dominant cleft palate-craniofacial disorder with variable expressivity. The
major features include cutaneous anomalies (cervical, infra- and/or supra-auricular defects, often with dermal thymus), ocular anoma-
lies, characteristic facial appearance (malformed pinnae, oral clefts), and, less commonly, renal and ectodermal (dental and hair) anom-
alies. The molecular basis for this disorder is heretofore unknown. We detected a 3.2 Mb deletion by 500K SNP microarray in an affected
mother and son with BOFS at chromosome 6p24.3. Candidate genes in this region were selected for sequencing on the basis of their
expression patterns and involvement in developmental pathways associated with the clinical ﬁndings of BOFS. Four additional BOFS
patients were found to have de novo missense mutations in the highly conserved exons 4 and 5 (basic region of the DNA binding do-
main) of the TFAP2A gene in the candidate deleted region. We conclude BOFS is caused by mutations involving TFAP2A.More patients
need to be studied to determine possible genetic heterogeneity and to establish whether there are genotype-phenotype correlations.Branchio-oculo-facial syndrome (BOFS [MIM 113620]) is
a distinctive rare disorder1 of the ﬁrst and second pharyn-
geal arches that includes thinned, erythematous cutaneous
defects in the cervical or infra- and/or supra-auricular re-
gion, ocular anomalies (microphthalmia or anophthalmia,
cataract, coloboma, strabismus, ptosis), and nasolacrimal
duct obstruction. The characteristic craniofacial features
are dolichocephaly, malformed pinnae, thick nasal tip,
up-slanted eyes, and cleft lip (CL) (often a lesser form
described as a microform, ‘‘pseudocleft,’’ or abnormal phil-
trum) with or without cleft palate (CP). Other common
ﬁndings are conductive hearing loss, ectodermal anoma-
lies (small teeth, dysplastic nails, sparse, prematurely gray
hair), ectopic dermal thymus, and scalp cysts. Less fre-
quent ﬁndings are renal anomalies, growth restriction, up-
per lip pits, and mild mental retardation. Autosomal-dom-
inant inheritance is well documented.1 Given the clinical
overlap with branchio-oto-renal syndrome, Kaiser et al.
used a candidate-gene approach to exclude most genes
in the EYA-DACH-SIX-PAX pathway,2 although a shared
37.37 Mb haplotype at chromosome 6p21.31-p25.3 was
found. We studied ﬁve families (European ancestry) in
which probands demonstrated all three BOFS features
(cervical skin defects, ocular anomalies, facial anomalies
[ﬁve patients]) or two features and a ﬁrst-degree affected
relative (one patient). Institutional Review Board (IRB) Re-
search informed consent and permission for publication of
photos was signed by each participant and/or parent.
Clinical features and pictures of each patient are shown
in Table 1.The AmGenome-wide microarrays have proven useful in the
identiﬁcation of genetic regions that are either deleted or
duplicated in speciﬁc malformation syndromes. These ge-
nomic alterations, even when found in a small percentage
of cases, can signiﬁcantly narrow the candidate region and
allow successful discovery of the gene (e.g., CHD7 [MIM
608892] in CHARGE syndrome [MIM 214800]).4 We used
the 500K SNP Affymetrix microarray to screen two spo-
radic BOFS patients and one affected mother and son
pair for cryptic chromosomal aberrations. Genomic DNA
was extracted with the AUTOPURE automated DNA extrac-
tor according to manufacturer’s instructions (Gentra
Systems, Minneapolis, MN). The 500K assay (Affymetrix,
Santa Clara, CA) consists of two 250K arrays and was per-
formed according to manufacturer’s protocol. Copy-num-
ber analysis was performed with the Affymetrix GeneChip
Genotyping Analysis software. This program combines the
two 250K arrays into a single virtual chip that can be
viewed for copy number. The arrays were compared against
a reference set of 25 previously deﬁned normal HapMap
samples. A 3.2 Mb deletion was detected in the mother
and son pair at chromosome 6p24.3 (Figure 1) in the pre-
viously implicated region harboring nine genes (based on
UCSC Genome Browser Human March 2006 Assembly;
Table 2). The two sporadic BOFS patients (BOFS pt. 2 and 3)
had no copy-number alterations in this region. Five poly-
morphic dinucleotide repeat markers were selected (three
ﬂanking and two from within the detected deleted region)
from the Genethon human linkage map HD-5 and MD-10
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Table 1. Molecular and Clinical Findings in BOFS Patients
Patient 1a 1b 2a 3 4 5b
Picture
DNA mutation Del 6p24.3
region
Del 6p24.3 region g. 10529 A/ G g. 10512 T/ C g. 10526 G/ A g. 12448 C/ T
Exon 4 4 4 5
Protein consequence R255G L249P R254G G262E
De novo? U No Yes Yes Yes Yes
Sex F M F M M F
Family history þ þ    
Age (years) 25 1 18 2 14 17
Branchial (Pharyngeal Arch) Anomalies
Cervical cutaneous
anomaly
þ R þ B þ B þ R þ B þ B
Dermal thymus U U þ   
Ocular Anomalies
Coloboma  þ R (iris, optic
nerve, retina)
þ R (iris)  þ R þ B (iris, retina)
Microphthalmia  þ R þ R  þ R þ B
Nasolacrimal duct
stenosis
  þ B þ B þ B 
Facial Anomalies
Auricular malformation þ þ þ þ þ þ
Characteristic face  þ mild þ þ þ þ
Chin dimple or cleft   Dimple Dimple  Cleft
Cleft lip and palate   (short tented
philtrum)
CL and P, B CL, B
(minimicroform)
CL, B
(microform)
CL, B
Facial nerve palsy    þ Right  
Preauricular pits    þ þ B þ R
Additional Features
CHD U U   U 
Dental anomalies   þ  þ þ
Growth restriction   þ (prenatal and
postnatal)
 þ (prenatal) þ (prenatal and
early childhood)
Hearing loss  þ B, R > L þ B þ þ þ B
Kidney anomalies     U þ Right (multicystic
dysplastic, VUR)
Lip pits      
Nail anomalies     þ þ
Prematurely gray hair þ    þ 
Scalp cysts  þ    
Sparse hair      þ
New Features
Anxiety, hypoplasia left
breast, precocious puberty
Depression,
medulloblastoma
The following abbreviations are used:þ, present;, absent; B, bilateral; CHD, congenital heart defect; CL, cleft lip; CP, cleft palate; CL and P, cleft lip and
palate; F, female; L, left; LDs, learning disabilities; M, male; R, right; U, unknown; and VUR, vesicoureteral reflux.
a Patient 2 reported previously in Lin et al., 1991 (patient 1),3 Lin et al., 1995,1 Lin et al. 2000.27
b Patient 5 reported in Lin et al., 1992,28 Lin et al., 2000.27Foster City, CA.) and conﬁrmed the chromosome 6 dele-
tion (Figure 2A). We then employed Multiplex Ligation-
dependent Probe Ampliﬁcation (MLPA) to assess whether1172 The American Journal of Human Genetics 82, 1171–1177, Maythe Activating enhancer-binding protein 2 alpha (TFAP2A
[MIM 107580]) gene was included in the deleted region.
A speciﬁc MLPA kit was not available to conﬁrm the2008
Figure 1. 500K SNP Microarray in BOFS Family 1
A 3.2 Mb deletion of 704 SNPs at 6p24.3 is shown with the UCSC genes inserted above the deletion.copy-number changes detected by the 500K microarray.
Two synthetic MLPA probes (from within exons 5 and 6
of the TFAP2A gene) were designed according to detailed
methodology (Medical Research Council [MRC], Holland).
The synthetic probes were added to an existing MLPA
kit and assayed according to standard protocols (MRC,
Holland). The results were analyzed with GENEMARKER
(SoftGenetics, State College, PA) and conﬁrmed the pres-
ence of a chromosome 6 deletion that included TFAP2A
(Figure 2B). Larger chromosomal deletions including this
region have been reported previously in patients with cleft
lip and palate.5 Although neither the affected mother nor
her son with BOFS in this report had overt cleft lip and
palate (CL and P), the boy does have an abnormally short
philtrum and bilateral notched vermilion-mucosa border,
which are on the spectrum of microform CL in BOFS.
Donnai et al. reported three members of a family with a
balanced translocation t(6;9)(p23;q22.3) who had CL and
P, malformed pinnae, nasolacrimal duct obstruction, up-
slanting palpebral ﬁssures, and premature graying, but
without the other typical BOFS facial gestalt and cutaneous
anomalies.5 Davies et al. described a boy with a larger dele-
tion of 6p24-p25 and multiple congenital anomalies (no
CL and P); although a photograph was not shown, the
ﬁndings are not those of BOFS.6 It remains unknown
whether the additional genes in the deleted region (TableThe Am2) have impacted the phenotype of family 1. None of the
genes have individually been associated with dominantly
inherited or deletion phenotypes.
Candidate genes in the deleted region were selected for
sequencing on the basis of their reported expression pat-
terns and known involvement in developmental pathways
associated with the clinical ﬁndings of BOFS (GeneCards,
Weizmann Institute of Science, Israel). Our mutation-de-
tection strategy was to polymerase chain reaction (PCR)
amplify and sequence the coding exons and the intron-
exon boundaries of each selected gene in the region. The
method used to sequence the gene utilizes the ABI Variant-
SEQr Resequencing system (Applied Biosystems, Foster
City, CA). Primer sequences for the generation of ampli-
cons were derived from the NCBI Gene website. The
mutation analysis was performed with the Mutation Sur-
veyor Program (SoftGenetics, State College, PA). No muta-
tions were found in BMP6 (MIM 112256), OFCC1, and
SLC35B3 (MIM 610845). TFAP2A was among the ﬁrst
four genes sequenced in the remaining four sporadic
BOFS patients. Deletions of the chromosomal region,
which include this gene, have previously implicated
TFAP2A as causing anterior ocular chamber anomalies.6
More recently, the TFAP2A gene has been shown to bind
to a regulatory element of IRF6 (MIM 607199) involved
in van der Woude syndrome (MIM 119300) (Rahimoverican Journal of Human Genetics 82, 1171–1177, May 2008 1173
Table 2. Genes Involved in Chromosome 6p24.3 Deletion in BOFS Family 1
Gene Symbol Gene Name Gene Function Expression
BMP6 bone morphogenetic protein 6 preproprotein Induces cartilage and bone formation Multiple tissues
CAGE1 cancer antigen1 Unknown Connective tissue; Prostate; Testis
DSP desmoplankin Involved in the organization of the
desmosomal cadherin-plakoglobin complexes
into discrete plasma-membrane domains and
in the anchoring of intermediate filaments to
the desmosomes
Ubiquitous
EEF1E1 eukaryotic translation elongation factor 1 Positive modulator of ATM response
to DNA damage
Ubiquitous
OFCC1 orofacial cleft 1 candidate 1 Unknown Testis
RIOK1 RIO Kinase1 Unknown Ubiquitous
SLC35B3 solute carrier family 35, member B3 Probable sugar transporter (by similarity) Ubiquitous
TFAP2A transcription factor AP-2 alpha See text See text
TXNDC5 thioredoxin domain containing 5 Possesses thioredoxin activity reducing
insulin disulfide bonds
Ubiquitouset al. ASHG 57th meeting A87, 2007). This is intriguing
because van der Woude syndrome is characterized by CL
and P with lower lip pits, whereas only upper lip pits are
seen in BOFS.
The AP-2 family of transcription factors bind to the
DNA consensus sequence GCCNNNGGC and stimulate
target-gene transcription, thus regulating gene expression
during embryogenesis of the eye, ear, face, body wall, limbs,
and neural tube.7–10 TFAP2A knockout mice exhibit abnor-
mal neural-crest-derived facial structures.11,12 Speciﬁcally,
this gene has been shown to regulate the development of
the facial prominences, limb buds, cranial closure, and lens
vesicle.7,13 Furthermore, Feng et al. have identiﬁed a con-
served Tcfap2a intronic enhancer element required for ex-
pression in facial and limb-bud mesenchyme in mice.141174 The American Journal of Human Genetics 82, 1171–1177, MaTFAP2A contains 437 amino acids and is a retinoic-acid-
responsive gene. TFAP2A has a central basic DNA binding
region, a carboxy terminus helix-span-helix motif that me-
diates dimerization, and an amino terminus that contains
a transactivation domain.15
De novo missense mutations were found in exons 4 and
5 (basic region of the DNA binding domain) of the TFAP2A
gene in the remaining four BOFS individuals (Table 1 and
Figure 3; paternity proven). The mutated amino acids are
highly conserved through the transparent sea squirt (Ciona
Intestinalis; Figure 4). The mutations detected by sequenc-
ing all occurred at natural restriction-enzyme sites. Restric-
tion digestion was performed with the appropriate enzyme
(New England Biolabs, Beverly, MA) speciﬁc to each muta-
tion. After the four sequencing mutations were conﬁrmed,Figure 2. Chromosome 6p24.3 Deletion in BOFS Family 1
(A) Microsatellite marker D6S309 showing absence of maternal allele (BOFS patient 1a) in her affected child (BOFS patient 1b) confirming
the chromosome 6p deletion.
(B) MLPA confirmation of TFAP2A gene deletion with two different intragenic probes (exons 5 and 6).y 2008
this method was used to screen 300 normal samples from
individuals of similar ethnicity. The four sequencing muta-
tions are not in the SNP database and were not found in
more than 300 normal individuals. The L249P alteration
(BOFS pt. 3) results in a predicted conformational space
change with the substituted proline. The R254W (BOFS
pt. 4) and R255G (BOFS pt. 2) alterations result in replace-
ment of a charged polar side chain by a nonpolar side
chain with a predicted conformational space change. The
G262E alteration (BOFS pt. 5) results in a nonpolar side
chain being replaced by a charged polar side chain. These
four alterations are predicted to be probably damaging by
PolyPhen and not tolerated by SIFT.
Figure 3. Sequence Chromatogram of TFAP2A Missense
Mutations
Numbering is according to NCBI: NC_000006.The AmGiven the variable expressivity of BOFS, it will be neces-
sary to study both classically affected cases having all three
features as well as those with minor phenotypes. With
strict inclusion criteria, some form of oral cleft was present
in all BOFS patients in the largest review of 43 patients
(54% microform CL).1 A deletion found in family 1 with-
out CL and P suggests that additional genotype-phenotype
studies are needed to determinewhether this is a consistent
observation and to determine the frequency of deletions
in BOFS.
BOFS patient 5 is the ﬁrst reported with medulloblas-
toma. TFAP2A has been shown to be involved in tumori-
genesis with protein expression levels affecting cell trans-
formation, tumor growth, metastasis, and survival.16–18
The tumor-suppressor activity of TFAP2A is mediated
through a direct interaction with p53 (MIM 191170), alter-
ing its transcriptional activity and stability.19,20 In addition,
TFAP2A suppresses the MYC (MIM 190080) oncogene.21
Both MYC and p53 are involved in medulloblastoma.
Expression studies on medulloblastoma tumor tissue from
patient 5 are planned.
As young teenagers, BOFS patients 2 and 5 had anxiety
and depression, respectively. Although this may be related
to the psychosocial context of having a craniofacial disor-
der, the AP-2 family may be involved in the regulation of
the monoaminergic systems in the adult brain, resulting
in neuropsychiatric disorders.22
We conclude that mutations involving TFAP2A result in
BOFS. More patients are needed to investigate genetic het-
erogeneity. Binding partners as well as other members of
the AP-2 family would be ideal candidates. The TFAP2A
gene appears to be responsible for all aspects of the recog-
nized phenotype. In family 1, the deletion phenotype may
be milder (lacking classic CL and P) because of haploinsuf-
ﬁciency of the gene or contiguous modiﬁer and/or en-
hancer genes. Hence, studies of additional BOFS patients
are necessary to establish whether there are any geno-
type-phenotype correlations. Previous linkage studies haveFigure 4. Evolutionary Conservation of
the Amino Acids in the TFAP2A Gene
Altered in BOFS Patients
Note the highly conserved amino acids from
Homo sapiens through Ciona intestinalis
in exons 4 and 5 of the TFAP2A gene.erican Journal of Human Genetics 82, 1171–1177, May 2008 1175
implicated the TFAP2A gene region in nonsyndromic CL
and P.23–25 In a timely review of murine genetic models
of CL and P, TFAP2Awas one of several previously unexam-
ined genes predicted to be a candidate gene for nonsyn-
dromic CL and P.26 By demonstrating that TFAP2A plays
an etiologic role in a CL and P syndrome, BOFS, its possible
role in nonsyndromic CL and P, especially lesser forms of
cleft lip, should be considered.
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